F-star Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own4.22% Shs Outstand21.08M Perf Week-1.49%
Market Cap135.03M Forward P/E- EPS next Y-2.33 Insider Trans0.00% Shs Float20.65M Perf Month125.63%
Income-33.50M PEG- EPS next Q-0.66 Inst Own54.80% Short Float1.35% Perf Quarter77.32%
Sales20.80M P/S6.49 EPS this Y80.60% Inst Trans-2.38% Short Ratio0.90 Perf Half Y24.16%
Book/sh4.18 P/B1.51 EPS next Y-10.00% ROA- Target Price26.75 Perf Year-25.24%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.07 - 8.51 Perf YTD25.40%
Dividend- P/FCF- EPS past 5Y27.80% ROI-28.50% 52W High-26.56% Beta1.02
Dividend %- Quick Ratio6.10 Sales past 5Y126.90% Gross Margin- 52W Low201.93% ATR0.40
Employees84 Current Ratio6.10 Sales Q/Q-10.30% Oper. Margin- RSI (14)78.08 Volatility2.35% 9.20%
OptionableYes Debt/Eq0.11 EPS Q/Q47.10% Profit Margin- Rel Volume1.83 Prev Close6.30
ShortableYes LT Debt/Eq0.11 EarningsMay 10 BMO Payout- Avg Volume307.39K Price6.25
Recom1.40 SMA2038.37% SMA5082.96% SMA20036.98% Volume475,938 Change-0.71%
Nov-18-21Resumed Ladenburg Thalmann Buy $15
Jun-24-22 08:06AM  
Jun-23-22 07:30AM  
May-14-22 08:44AM  
May-10-22 08:00AM  
May-02-22 09:00AM  
Apr-08-22 08:00AM  
Mar-21-22 04:12PM  
Mar-14-22 08:00AM  
Mar-10-22 08:00AM  
Mar-02-22 08:00AM  
Mar-01-22 08:00AM  
Jan-20-22 08:00AM  
Jan-07-22 08:00AM  
Jan-05-22 08:00AM  
Dec-07-21 09:05AM  
Nov-29-21 08:00AM  
Nov-12-21 08:00AM  
Nov-11-21 08:30AM  
Nov-10-21 08:00AM  
Nov-01-21 08:00AM  
Oct-20-21 08:00AM  
Sep-16-21 08:00AM  
Sep-09-21 09:00AM  
Aug-12-21 08:00AM  
Aug-10-21 08:00AM  
Aug-04-21 08:00AM  
Aug-02-21 10:10AM  
Jul-26-21 08:00AM  
Jul-09-21 08:00AM  
Jul-08-21 08:00AM  
May-17-21 08:00AM  
May-10-21 08:00AM  
May-07-21 07:00AM  
May-06-21 04:50PM  
Apr-19-21 09:27AM  
Apr-16-21 11:39AM  
Apr-10-21 09:22AM  
Apr-01-21 08:00AM  
Mar-29-21 08:00AM  
Mar-17-21 03:44AM  
Mar-16-21 08:00AM  
Mar-04-21 08:00AM  
Jan-20-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 08:00AM  
Dec-03-20 08:00AM  
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kayitalire LouisChief Medical OfficerNov 02Sale6.836443754,255Nov 04 09:34 PM
Kayitalire LouisChief Medical OfficerOct 04Sale7.236446254,319Oct 06 04:38 PM